The China Migraine therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
China is the world’s largest number of migraine prevalence: Despite the prevalence, Italy is China’s 2 times the number of patients with migraine in China are more than 132 million and the prevalence of migraine in women is 3 times more frequent than in the men. In recent years, although foreign migraine treatment drugs continue to introduce new and optimistic performance, the domestic market for migraine drugs still seems to have insufficient stamina. According to CMH’s statistics, the overall size of the migraine medication market zolmitriptan, tofu, and rizatriptan accounted for 90.45% of the total market share.
Growing awareness about migraine and its treatment options, increasing R&D expenditures leading to high pipeline products, increasing the prevalence of migraines along high unmet needs are the major factors that are supporting the growth of the migraine therapeutics market globally. The World Health Organization’s disability rating for migraine ranks it as the 19th most common reason for disability. this increasing prevalence of migraines allows the usage of more and more therapeutics to get relief, and this helps in driving the overall market. However, lack of proper diagnosis and undiagnosed cases, adverse effects of drugs, increased preference for alternative therapies, and generic penetration are the few factors hampering the migraine therapeutics market.